Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors 2Tracheal Diseases 1TP53 Y220C Mutation 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lung Neoplasms 1Laryngeal Diseases 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Adenoid Cystic 1Advanced Solid Tumors 1

Interventions

repaglinide 1Tablets 1Rosuvastatin Calcium 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
TP53 Y220C Mutation × Tablets × Other solid neoplasm × Clear all
NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

PMV Pharmaceuticals, Inc

Phase 1 Recruiting
14 enrolled
Other solid neoplasm

TP53 Y220C Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡